HINDUNILVR vs SUNPHARMA: Stock Comparison
HINDUSTAN UNILEVER is the larger company by market capitalisation. HINDUSTAN UNILEVER shows a lower P/E, a higher ROE and a higher dividend yield, while SUN PHARMACEUTICAL IND L shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
HINDUNILVR leads 6; SUNPHARMA leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | HINDUNILVR | SUNPHARMA |
|---|---|---|
| Sector | Fast Moving Consumer Goods | Healthcare |
| Industry | Diversified FMCG | Pharmaceuticals |
Price
| Metric | HINDUNILVR | SUNPHARMA |
|---|---|---|
| Live Price | ₹1,895.2 | ₹1,804.1 |
| Day Change | 3.09% | 1.37% |
| Volume | 15.76 L | 14.78 L |
| 52-Week High | ₹2,667.2 | ₹2,046.9 |
| 52-Week Low | ₹1,826.9 | ₹1,583.7 |
| Distance from 52W High | -28.94% | -11.86% |
Valuation
| Metric | HINDUNILVR | SUNPHARMA |
|---|---|---|
| Market Cap | ₹4.45 L Cr | ₹4.32 L Cr |
| P/E Ratio | 28.9x | 35.35x |
| P/B Ratio | 8.87x | 5.12x |
| EPS | ₹44.66 | ₹49.8 |
| Book Value | ₹207.44 | ₹348.31 |
| Dividend Yield | 2.4% | 0.89% |
Growth
| Metric | HINDUNILVR | SUNPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | 4.3% | 12.8% |
| EPS Growth (TTM YoY) | 21.4% | 25.6% |
| Qtr Sales Growth | 4.11% | 166.5% |
| Qtr Profit Growth | 1.86% | 160.17% |
Profitability & Leverage
| Metric | HINDUNILVR | SUNPHARMA |
|---|---|---|
| ROE | 22.25% | 13.72% |
| ROCE | 23.44% | 15.12% |
| Net Margin | 23.25% | 18.56% |
| Operating Margin | 22.77% | 26.44% |
| Debt to Equity | 0x | 0.05x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | HINDUNILVR | SUNPHARMA |
|---|---|---|
| Promoter Holding | 0% | 54.48% |
| FII Holding | 9.5%▼ 0.6 pp | 14.53%▼ 1.4 pp |
| DII Holding | 16.99%▲ 0.59 pp | 22.18%▲ 1.07 pp |
| Public Holding | 11.61%▲ 0.01 pp | 8.81%▲ 0.33 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: HINDUSTAN UNILEVER and SUN PHARMACEUTICAL IND L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.